Search Results

278 Results for "amylyx".

Sort By

Regulatory

FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.

January 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases

Amylyx Pharmaceuticals to Participate in Upcoming March 2025 Investor Conferences

February 26, 2025
·
1 min read
Press Releases

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025
·
15 min read
Deals

Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

While supportive of Amylyx’s acquisition of a GLP-1 drug, analysts say the company’s future hinges on key upcoming readouts from multiple products in its pipeline.

July 24, 2024
·
5 min read
·
Heather McKenzie
Press Releases

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

February 24, 2025
·
1 min read
Press Releases

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 10, 2025
·
1 min read
Press Releases

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 10, 2025
·
4 min read
Press Releases

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 10, 2025
·
3 min read
Press Releases

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

January 7, 2025
·
8 min read
Genetown

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of America Health Care Conference.

May 8, 2024
·
1 min read